Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca's Prostate-Cancer Propel Phase 3 Trial Met Primary Point

09/24/2021 | 12:31am EDT

By Sabela Ojea

AstraZeneca PLC said Friday that the Propel Phase 3 trial met its primary point, proving that its Lynparza drug significantly delayed disease progression of first-line metastatic castration-resistant prostate cancer in combination with the abiraterone drug.

The biopharmaceutical company said the results from the trial showed positive results, including a trend towards improved overall survival.

The London-listed company noted that prostate cancer is the second most common cancer.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

09-24-21 0231ET

All news about ASTRAZENECA PLC
10:08aTens of millions of J&J COVID-19 shots sit at Baltimore factory -sources
RE
06:00aTens of millions of J&J COVID-19 shots sit at Baltimore factory -sources
RE
10/27VACCINATED BUT STUCK : Indians await WHO nod for homegrown shot to travel abroad
RE
10/26ASTRAZENECA : Deutsche Bank reiterates its Buy rating
MD
10/26VACCINATED BUT STUCK : Indians await WHO nod for homegrown shot to travel abroad
RE
10/25AstraZeneca PLC Announces Positive High-Level Results from the TOPAZ-1 Phase III Trial
CI
10/25ASTRAZENECA : Daiichi Sankyo in Clinical Trial Collaboration to Evaluate Datopotamab Derux..
MT
10/25WALL STREET STOCK EXCHANGE : 84% of Q3 earnings reports exceed expectations
10/25ANALYST RECOMMENDATIONS : American Express, Beyond Meat, Microsoft, Oracle, Weibo...
10/25UNIVERSITY OF BIRMINGHAM : A third of leukaemia patients do not generate any antibody resp..
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 419 M - -
Net income 2021 4 854 M - -
Net Debt 2021 24 729 M - -
P/E ratio 2021 35,8x
Yield 2021 2,28%
Capitalization 193 B 194 B -
EV / Sales 2021 6,14x
EV / Sales 2022 4,96x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 123,49 $
Average target price 138,33 $
Spread / Average Target 12,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC22.80%191 297
JOHNSON & JOHNSON4.04%431 043
ROCHE HOLDING AG14.74%335 888
NOVO NORDISK A/S59.43%242 507
PFIZER, INC.18.34%240 919
ELI LILLY AND COMPANY48.17%226 799